Health Affairs
IRA Litigation: Pharma’s Failed Challenges To Medicare Drug Pricing
To date, every court that has considered substantive challenges to the Medicare drug price negotiation program has ruled ...
BioNTech founders plan exit to set up new venture, shares slump
BioNTech's two co-founders and leading executives will leave the COVID-19 vaccine maker by the end ‌of the year to start a ...
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel
Capricor Therapeutics (CAPR) upgraded to Buy as FDA accepts HOPE-3 for Deramiocel in DMD cardiomyopathy; PDUFA Aug 22, 2026.
The Motley Fool
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 ...
MassDevice
Medtronic makes neurovascular play with $550M Scientia Vascular buy
Medtronic announced today that it has entered into a definitive agreement to acquire Scientia Vascular for $550 million.
24/7 Wall St.
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained
Wall Street is drawing fresh lines across the large-cap biopharma landscape, initiating coverage on two stocks and maintaining an overweight rating on another.